Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Achillion Pharmaceuticals, Inc. (NQ: ACHN)
7.770 USD  +0.210 (+2.78%)
Official Closing Price  /  Updated: 8:10 PM EDT, May 17, 2013  /  Add to My Watchlist      
View: Quote News Research
All news about Achillion Pharmaceuticals, Inc.
 
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Achillion (ACHN) Announces Positive ACH-1625 Hepatitis C Results
May 11, 2010
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=5623270 for the full story. Read More
from StreetInsider.com News Articles
Achillion Announces Positive Once-Daily Dosing Results With ACH-1625 to Treat Hepatitis C
May 11, 2010
from GlobeNewswire News Releases
FDA Makes InterMune Sick (ITMN, GSK, AZN, GILD, VRTX, ACHN, VRUS)
May 10, 2010
Should investors hang on despite a devastating FDA decision? Read More
from Investopedia Advisor Commentary
Achillion Pharma (ACHN) Posts Q1 Loss of $0.16, Beats Views
May 10, 2010
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=5613285 for the full story. Read More
from StreetInsider.com News Articles
Achillion Reports First Quarter Financial Results
May 10, 2010
from GlobeNewswire News Releases
Achillion Pharma (ACHN) Presents Data from ACH-1625 HCV Treatment
April 15, 2010
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=5531796 for the full story. Read More
from StreetInsider.com News Articles
Achillion Presents Data From Studies of ACH-1625 in Hepatitis C at the EASL International Liver Congress
April 15, 2010
ACH-1625 Achieves Significant Viral Load Reduction and Sustained Viral Suppression With Continued Safety and Tolerability Read More
from GlobeNewswire News Releases
Achillion's 'Very Promising' New Drug for Hepatitis C
April 14, 2010
Viral hepatitis is the leading cause of liver cancer and the most common reason for a liver transplant, but few treatments exist. CEO Mike Kishbauch explains how Achillion is trying to change that.... Read More
category hepatitis C , gild , achn , and 4 more.
from DailyFinance.com
Achillion Pharma (ACHN) Announces Receipt of Phase 1 SBIR Grant for ACH-702 Antibacterial
March 18, 2010
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=5449682 for the full story. Read More
from StreetInsider.com News Articles
Achillion Announces Award of NIH Grant to Study Unique Antibacterial Compound Series
March 18, 2010
from GlobeNewswire News Releases
Achillion to Present ACH-1625 Protease Inhibitor Abstracts at International Liver Congress
March 16, 2010
from GlobeNewswire News Releases
Achillion Pharma (ACHN) Posts Q4 Loss of $0.25, Misses Views; Revs Light
March 12, 2010
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=5432833 for the full story. Read More
from StreetInsider.com News Articles
Achillion Reports 2009 Fourth Quarter and Year-End Financial Results
March 12, 2010
from GlobeNewswire News Releases
Achillion to Present at Upcoming Investor Conferences
March 05, 2010
from GlobeNewswire News Releases
21st Annual Analyst Conference Taking Place March 12th, 2010 at The University Club (54th & 5th Ave)
February 23, 2010
from Business Wire News Releases
Achillion Pharma (ACHN) Updates on Elvucitabine Phase 2
February 17, 2010
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=5355712 for the full story. Read More
from StreetInsider.com News Articles
Achillion Announces Positive 96-Week Data for Elvucitabine at the 17th Annual Conference on Retroviruses and Opportunistic Infections
February 17, 2010
from GlobeNewswire News Releases
Achillion to Present at 12th Annual BIO CEO and Investor Conference
February 08, 2010
from GlobeNewswire News Releases
The Week in Review: New Investments in China Life Science
February 06, 2010
BioMarin Pharma will pay up to $96 million to acquire LEAD Therapeutics, which is connected to ShangPharma; Tongjitang Chinese Medicines will acquire Guiyang Liquor Factory for $17.7 million; Zhejiang... Read More
from ChinaBio® Today
Achillion Announces Closing of Underwriters' Over-Allotment Option
February 02, 2010
from GlobeNewswire News Releases
Notable Analyst Rating Changes 02/02: AA, Q, AXP, FCX, ACHN Upgraded; JEC, VCLK, AVAV Downgraded
February 02, 2010
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=5298506 for the full story. Read More
from StreetInsider.com News Articles
Pre-Market Stock Upgrades/Downgrades Feb 2, 2010
February 02, 2010
category stock initiations , Wall Street , Business , and 2 more.
from Wall Street Pit
Wedbush Upgrades Achillion Pharmaceuticals (ACHN) to Outperform
February 02, 2010
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=5297674 for the full story. Read More
from StreetInsider.com News Articles
GCA Therapeutics to Commercialize Achillion’s HBV Treatment in China
February 02, 2010
Achillion Pharmaceuticals out-licensed the China rights for elvucitabine, to GCA Therapeutics, Ltd. (GCAT) of Jersey City, New Jersey. Elvucitabine is a nucleoside reverse transcriptase inhibitor... Read More
from ChinaBio® Today
Achillion Pharmaceuticals (ACHN) Annouinces License Agreement for Elvucitabine Development in China
February 01, 2010
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=5295089 for the full story. Read More
from StreetInsider.com News Articles
Achillion Announces License Agreement for Elvucitabine Development in China
February 01, 2010
from GlobeNewswire News Releases
Skymark Research Initiates Independent Research Coverage on Achillion Pharmaceuticals, Inc.
January 29, 2010
from GlobeNewswire News Releases
Inside Wall Street: 2010 Could Be Big for Small Biotechs
January 29, 2010
Biotechnology stocks pulled a huge surprise in 2009: They surged. Few analysts expected the sector to handily outscore the rest of the market. Equally surprising was the robust performance of the young... Read More
category RXII , BiotechStocks , pharmaceutical stocks , and 23 more.
from DailyFinance.com
Achillion Announces Nomination of ACH-2684 as Lead Clinical Candidate in Resistance-Focused HCV Program
January 28, 2010
Compound Demonstrates Excellent Potency Against HCV and Retains Activity Against Resistant Variants Read More
from GlobeNewswire News Releases
Achillion to Host Corporate and Clinical Update Conference Call on Monday, February 1, 2010
January 25, 2010
from GlobeNewswire News Releases
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here